General Surgery, Kailuan General Hospital, Tangshan, Heibei, 063000, China.
Department of Breast Surgery, Yuncheng Central Hospital, Yuncheng, 044000, China.
Future Oncol. 2024 May;20(14):951-958. doi: 10.2217/fon-2021-1152. Epub 2023 Nov 29.
To explore the clinical application value of indocyanine green (ICG)-rituximab in sentinel lymph node biopsy. This study included 156 patients with primary breast cancer: 50 patients were enrolled in dose-climbing test, and 106 patients were enrolled in verification test. This was to compare the consistency of ICG-rituximab and combined method in the detected lymph nodes. According to the verification test, the imaging rate of ICG-rituximab was 97.3%. Compared with the combined method, the concordance rate of fluorescence method was 0.991 (28 + 78/107; p < 0.001). For ICG-rituximab as a fluorescent targeting tracer, the optimal imaging dose of ICG 93.75 μg/rituximab 375 μg can significantly reduce the imaging of secondary lymph nodes. Compared with the combined method, it has a higher concordance rate.
探讨吲哚菁绿（ICG）-利妥昔单抗在前哨淋巴结活检中的临床应用价值。本研究纳入了 156 例原发性乳腺癌患者：50 例患者纳入剂量爬坡试验，106 例患者纳入验证试验。旨在比较 ICG-利妥昔单抗与联合方法检测的淋巴结的一致性。根据验证试验，ICG-利妥昔单抗的成像率为 97.3%。与联合方法相比，荧光法的符合率为 0.991（28+78/107；p<0.001）。对于 ICG-利妥昔单抗作为荧光靶向示踪剂，ICG 的最佳成像剂量为 93.75μg/利妥昔单抗 375μg，可显著减少二级淋巴结的成像。与联合方法相比，具有更高的符合率。
